AI
VIRX

Atria Investments’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Atria Investments’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-460
Closed -$20K – 1097
2019
Q1 		$20K Sell
460
-39
-8% -$884 ﹤0.01% 916
2018
Q4 		$7K Buy
+499
New +$20.4K ﹤0.01% 874

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Atria Investments's VIRX Position: Q2 2019 in Review

Atria Investments sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2019, closing a stake of 460 shares — an estimated $20K sold.

Atria Investments first reported a position in VIRX in Q4 2018 and held it in 2 quarters. The position peaked at $20K in Q1 2019. 45 funds tracked by Wall St. Rank hold VIRX as of Q2 2019.

  • Atria Investments reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Atria Investments sold 460 Viracta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $20K.
  • Atria Investments first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Atria Investments's Viracta Therapeutics, Inc. Common Stock position peaked at $20K in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Atria Investments's 13F filing for Q2 2019, filed 9 Aug 2019.